Polio Resurgence Raises Vaccination Concerns: Global Public Health Alert
Recent polio cases in Israel, Malawi, Afghanistan, and Pakistan underscore the ongoing threat of poliovirus transmission and the importance of maintaining high vaccination coverage to prevent outbreaks and achieve global polio eradication goals.
November 2022
Durability of Anti-Spike Antibodies in Infants: Implications for Maternal Vaccination
Most infants born to COVID-19 vaccinated mothers exhibit persistent anti-spike (anti-S) antibodies at six months, highlighting the potential duration of maternal antibody transfer and passive immunity in newborns, and supporting the benefits of maternal vaccination for infant health.
November 2022
FDA Fully Approves Moderna COVID-19 Vaccine: Name Change and Regulatory Status
The FDA grants full approval to the Moderna COVID-19 vaccine, allowing it to be marketed under the name Spikevax, reflecting its transition from emergency authorization to full regulatory approval based on safety and efficacy data.
October 2022
Herd Immunity Unlikely for COVID-19: Public Health Implications
Achieving herd immunity against COVID-19 is unlikely, necessitating continued vaccination efforts, treatment development, and ensuring adequate healthcare capacity to mitigate the impact of the ongoing pandemic and prevent future surges in infections.
October 2022
Frequency of Adverse Events in Placebo Arms of COVID-19 Vaccine Trials: Clinical Insights
A significant proportion of adverse events reported in placebo arms of COVID-19 vaccine trials are attributable to the placebo effect, highlighting the importance of placebo-controlled trials in assessing vaccine safety and efficacy.
October 2022
Promising Results of Zika Vaccine: Preclinical Efficacy Insights
A Zika virus vaccine candidate demonstrates efficacy in preventing vertical transmission from mother to fetus in preclinical animal studies, offering promising prospects for Zika virus prevention and control strategies in human populations.
October 2022
Paths to Super Immunity for COVID-19: Laboratory Research Insights
New laboratory research reveals multiple paths to robust immunity against COVID-19, providing insights into immune responses and informing vaccine development strategies to enhance protective immunity against emerging SARS-CoV-2 variants.
September 2022
Rare Incidence of Multisystem Inflammatory Syndrome in Vaccinated Children: Vaccine Recommendations
Multisystem inflammatory syndrome is rare in vaccinated children, supporting COVID-19 vaccination recommendations for everyone aged 5 and older in the United States to protect against severe illness and complications associated with SARS-CoV-2 infection.
September 2022
Clinical Trial of Omicron Variant-Based Vaccine: Phase III Study Initiated
A phase III clinical trial of a vaccine based on the Omicron variant begins, aiming to evaluate different dosing regimens in adult volunteers without comorbidities and assess the vaccine’s efficacy and safety for potential use as a booster dose.
September 2022
FDA Endorses Pfizer Booster Vaccine for Children 12-15 Years Old: Expanded Recommendations
The FDA endorses the Pfizer booster vaccine for children aged 12-15 years old and authorizes an additional dose for immunocompromised children aged 5-11 years old, alongside shortened intervals for booster doses, aiming to enhance vaccine coverage and protection against COVID-19 in pediatric populations.
September 2022
